CAS: 65-45-2; 2-Hydroxybenzamide

上下游产品

CAS号611-20-1 水杨腈 | CAS号89-95-2 邻甲基苄醇 | CAS号94-67-7 水杨醛肟 | CAS号90-02-8 水杨醛 | CAS号17999-25-6 2-hydroxythiobe... | CAS号29579-11-1 2-(苄氧基)苯甲酰胺 | CAS号2439-77-2 2-甲氧基苯甲酰胺 | CAS号119-36-8 水杨酸甲酯 | CAS号69-72-7 水杨酸 | CAS号112107-45-6 2-(trifluoromet... | CAS号40187-51-7 5-乙酰基水杨酰胺 | CAS号3411-95-8 2-(2-羟苯基)苯并噻唑 | CAS号143000-14-0 9-oxo-9-phenyl-... | CAS号142976-54-3 3-(hydroxymethy... | CAS号14520-53-7 2-prop-2-enoxyb... | CAS号143000-05-9 2-phenyl-2,3-di... | CAS号938-73-8 2-乙氧基苯甲酰胺 | CAS号18071-54-0 3,5-Diiodo-2-hy... | CAS号20602-57-7 4H-1,3-BENZOXAZ...

水杨酸苯酯置于sodium Hydroxide,氨体系中,用 水,乙腈 作为反应溶剂,化学反应生成 水杨酰胺
参考文献:Khan,Mohammad Niyaz,Journal Of The Chemical Society. Perkin Transactions Ii,1989,P. 199-208
标题:Khan,Mohammad Niyaz,Journal Of The Chemical Society. Perkin Transactions Ii,1989,P. 199-208

专利信息

专利号:US-2012177593-A1
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates
发明人：BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

专利号:WO-2024013769-A1
优先权日:2022-07-12
标题:Process for solvent free continuous synthesis of amides and peptides
发明人：KULKARNI AMOL ARVINDRAO; ATAPALKAR RANJIT SHABU
权利人:COUNCIL SCIENT IND RES
摘要:The present invention relates to a novel process for the solvent free continuous synthesis of amides and peptides. More particularly, the invention relates to a process for synthesizing amides and peptides using coupling reagents where the process is done at room temperature with lower residence time and solvent free synthesis, producing enhanced yields and purity products.

专利号:US-8293290-B2
优先权日:2003-04-08
标题:Annatto extract compositions, including geranyl geraniols and methods of use
发明人：TAN BARRIE
权利人:TAN BARRIE; AMERICAN RIVER NUTRITION INC
摘要:Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-8304409-B2
优先权日:2002-07-03
标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
发明人：EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

专利号:US-4202714-A
优先权日:1970-09-11
标 题:Ballistic modifiers and synthesis of the ballistic modifiers
发明人：ALLEY BERNARD J; DAKE JAMES D; DYKES HIRAM W H
权利人:US ARMY
摘要:A new class of ballistic modifiers and the synthesis thereof is disclosed herein and are used in propellants either individually or as admixtures in percentages of approximately 0.5 to 6 weight percent to impart mesa or plateau burning rate characteristics over a wide pressure range and reduce the temperature sensitivity of the propellants in relation to burning rates. The modifiers are chelate type compounds comprised of lead and/or copper, and various predetermined molar ratios of compounds such as salicylic acid and beta-resorcylic acid.